業績紹介

Achivement

2020年業績

• Ogawa Y, Kobayashi T, Honda Y, Kessoku T, Tomeno W, Imajo K, Nakahara T, Oeda S, Nagaoki Y, Amano Y, Ando T, Hirayama M, Isono O, Kamiguchi H, Nagabukuro H, Ogawa S, Satomi Y, Saigusa Y, Takahashi H, Hyogo H, Yoneda M, Saito S, Yamanaka T, Aishima S, Eguchi Y, Kage M, Chayama K and Nakajima A.

  Metabolomic-/Lipidomic-based Analysis of Plasma to Diagnose Hepatocellular Ballooning in Patients with Nonalcoholic Fatty Liver Disease: A Multicenter Study.

  Hepatol Res . 2020; In Press.

• Nakamura K, Urabe Y, Oka S, Nagasaki N, Yorita N, Hata K, Masuda K, Kurihara M, Kotachi T, Boda T, Tanaka S and Chayama K.

  Usefulness of linked color imaging in the early detection of superficial esophageal squamous cell carcinomas.

  Esophagus . 2020; In Press.

• Fukiage A, Fujino H, Miki D, Ishii Y, Serikawa M, Tsuge M, Imamura M, Aikata H, Hayes CN and Chayama K.

  Clinical Usefulness of Serum Autotaxin for Early Prediction of Relapse in Male Patients with Type 1 Autoimmune Pancreatitis.

  Dig Dis Sci . 2020; In Press.

• Dasgupta S, Imamura M, Gorstein E, Nakahara T, Tsuge M,Churkin A, Yardeni D, Etzion O, Uprichard SL, Barash D, Cotler SJ, Dahari H and Chayama K.

  Modeling-based response-guided therapy for chronic hepatitis C under glecaprevir / pibrentasvir may identify patients for ultra-short treatment duration.

  J Infect Dis . 2020; In Press.

• Okubo Y, Nakano Y, Ochi H, Onohara Y, Tokuyama T, Motoda C, Amioka M, Hironobe N, Okamura S, Ikeuchi Y, Miyauchi S, Chayama K and Kihara Y.

  Predicting atrial fibrillation using a combination of genetic risk score and clinical risk factors.

  Heart Rhythm . 2020; 17: 699-705.

• Juhling F, Hamdane N, Crouchet E, Li S, El Saghire H, Mukherji A, Fujiwara N, Oudot MA, Thumann C, Saviano A,Roca Suarez AA, Goto K, Masia R, Sojoodi M, Arora G, Aikata H, Ono A, Tabrizian P, Schwartz M, Polyak SJ, Davidson I, Schmidl C,Bock C, Schuster C, Chayama K, Pessaux P, Tanabe KK, Hoshida Y, Zeisel MB, Duong FH, Fuchs BC and Baumert TF.

  Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.

  Gut . 2020; In Press.

• Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y,Iwamoto A, Kajikawa M, Matsumoto T, Oda N, Kishimoto S, Matsui S, Hashimoto H, Takaeko Y, Yamaji T, Harada T, Han Y, Aibara Y, Mohamad Yusoff F, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Goto C, Tomiyama H, Takase B, Kohro T, Suzuki T, Ishizu T, Ueda S, Yamazaki T, Furumoto T, Kario K, Inoue T, Koba S, Watanabe K, Takemoto Y, Hano T, Sata M, Ishibashi Y, Node K, Maemura K, Ohya Y, Furukawa T, Ito H, Ikeda H, Yamashina A and Higashi Y.

  Increased arterial stiffness and cardiovascular risk prediction in controlled hypertensive patients with coronary artery disease: post hoc analysis of FMD-J (Flow-mediated Dilation Japan) Study A.

  Hypertens Res .2020; In Press.

• Morio K, Kawaoka T, Aikata H, Namba M, Uchikawa S, Kodama K, Ohya K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Imamura M,Nakamura Y, Akagi M, Awai K, Kobayashi T, Ohdan H and Chayama K.

  Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection.

  Eur J Radiol . 2020; 124: 108828

• Okamoto Y, Oka S, Tanaka S, Inagaki K, Tanaka H, Matsumoto K, Boda K, Yamashita K, Sumimoto K, Ninomiya Y and Chayama K.

  Clinical usefulness of the S-O clip during colorectal endoscopic submucosal dissection in difficult-to-access submucosal layer.

  Endosc Int Open . 2020; 8: E437-E444.

• Kuroki K, Sanomura Y, Oka S, Yorita N, Kurihara M, Mizumoto T, Yoshifuku Y, Arihiro K, Tanaka S and Chayama K.

  Clinical outcomes of endoscopic resection for superficial non-ampullary duodenal tumors.

  Endosc Int Open . 2020; 8: E354-E359.

• Fujita M, Yamaguchi R, Hasegawa T, Shimada S, Arihiro K,Hayashi S, Maejima K, Nakano K, Fujimoto A, Ono A, Aikata H, Ueno M, Hayami S, Tanaka H, Miyano S, Yamaue H, Chayama K, Kakimi K, Tanaka S, Imoto S and Nakagawa H.

  Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations.

  EBioMedicine .2020; 53: 102659.

• Suleiman AA, Lin CW, Liu W, Eckert D, Mensing S, Burroughs M,Kato K, Chayama K, Kumada H and Oberoi RK.

  Population Pharmacokinetics of Glecaprevir / Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials.

  J Clin Pharmacol .2020; 60: 331-339.

• Oshita K, Ohira M, Honmyo N, Kobayashi T, Murakami E, Aikata H, Baba Y, Kawano R, Awai K, Chayama K and Ohdan H.

  Treatment outcomes after splenectomy with gastric devascularization or balloon-occluded retrograde transvenous obliteration for gastric varices: a propensity score-weighted analysis from a single institution.

  J Gastroenterol . 2020; In Press.

• Kumada T,Toyoda H, Yasuda S, Tada T, Ogawa S, Takeshima K, Tanaka J, Chayama K and Johnson PJ.

  Impact of the introduction of direct-acting anti-viral drugs on hepatocarcinogenesis: a prospective serial follow-up MRI study.

  Aliment Pharmacol Ther .2020; In Press.

• Takeuchi Y, Tsuge M, Tsushima K, Suehiro Y, Fujino H, Ono A, Yamauchi M, Makokha GN, Nakahara T, Murakami E, Abe-Chayama H, Kawaoka T, Miki D, Imamura M, Aikata H, Hayes CN, Tateno C and Chayama K.

  Signal activation of hepatitis B virus-related hepatocarcinogenesis by upregulation of SUV39h1.

  J Infect Dis . 2020; In Press.

• Ishigaki K, Akiyama M, Kanai M, Takahashi A, Kawakami E, Sugishita H, Sakaue S, Matoba N, Low SK, Okada Y, Terao C, Amariuta T, Gazal S,Kochi Y, Horikoshi M, Suzuki K, Ito K, Koyama S,Ozaki K, Niida S, Sakata Y, Sakata Y, Kohno T, Shiraishi K, Momozawa Y, Hirata M, Matsuda K, Ikeda M, Iwata N, Ikegawa S, Kou I,Tanaka T, Nakagawa H, Suzuki A, Hirota T, Tamari M,Chayama K, Miki D, Mori M, Nagayama S, Daigo Y, Miki Y, Katagiri T, Ogawa O, Obara W, Ito H, Yoshida T, Imoto I, Takahashi T, Tanikawa C, Suzuki T, Sinozaki N, Minami S, Yamaguchi H, Asai S, Takahashi Y, Yamaji K,Takahashi K, Fujioka T, Takata R, Yanai H, Masumoto A, Koretsune Y, Kutsumi H,Higashiyama M, Murayama S, Minegishi N, Suzuki K, Tanno K, Shimizu A, Yamaji T, Iwasaki M, Sawada N, Uemura H, Tanaka K, Naito M, Sasaki M, Wakai K, Tsugane S, Yamamoto M, Yamamoto K, Murakami Y,Nakamura Y, Raychaudhuri S, Inazawa J, Yamauchi T, Kadowaki T, Kubo M and Kamatani Y.

  Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases.

  Nat Genet . 2020; In Press.

• Cheng X, Uchida T, Xia Y, Umarova R, Liu CJ,Chen PJ, Gaggar A, Suri V, Mucke MM, Vermehren J, Zeuzem S, Teraoka Y, Osawa M, Aikata H, Tsuji K, Mori N, Hige S, Karino Y, Imamura M, Chayama K and Liang TJ.

  Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection.

  J Clin Invest . 2020; 130:3205-3220.

• Takehara T, Chayama K, Kurosaki M, Yatsuhashi H, Tanaka Y, Hiramatsu N, Sakamoto N, Asahina Y, Nozaki A, Nakano T, Hagiwara Y, Shimizu H, Yoshida H, Huang Y, Biermer M, Vijgen L and Hayashi N.

  JNJ-4178 ( adafosbuvir , odalasvir ,and simeprevir ) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study.

  J Gastroenterol . 2020; 55: 640-652.

• Masuda K, Urabe Y, Ito M, Ono A, Clair Nelson H, Nakamura K, Kotachi T, Boda T, Tanaka S and Chayama K.

  Correction to:Genomic landscape of epithelium with low-grade atypia on gastric cancer after Helicobacter pylori eradication therapy.

  J Gastroenterol . 2020; 55: 666.

• Tamura Y, Kawaoka T, Aikata H, Namba M, Fujii Y, Morio K, Murakami E, Yamauchi M, Hiramatsu A, Nakahara T, Imamura M, Maruhashi T, Kobayashi T, Ohdan H, Kimura T, Nagata Y, Arihiro K and Chayama K.

  Isolated cardiac metastases of hepatocellular carcinoma after resection: a case report.

  Clin J Gastroenterol .2020; 13: 421-427.

• Kuwashiro T, Takahashi H, Hyogo H,Ogawa Y, Imajo K, Yoneda M,Nakahara T, Oeda S, Tanaka K, Amano Y, Ogawa S,Kawaguchi A, Aishima S, Kage M, Chayama K, Nakajima A and Eguchi Y.

  Discordant pathological diagnosis of non-alcoholic fatty liver disease: A prospective multicenter study.

  JGH Open . 2020; 4: 497-502.

• Kosaka Y, Kawaoka T, Aikata H, Suehiro Y,Yamaoka K, Ando Y, Namba M, Takeuchi Y, Fujii Y, Uchikawa S, Kodama K, Oya K, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Imamura M,Baba Y, Awai K, Kimura T, Nagata Y and Chayama K.

  A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk.

  Clin J Gastroenterol . 2020; In Press.

• Maruhashi T, Kajikawa M, Kishimoto S, Hashimoto H, Takaeko Y, Yamaji T, Harada T, Han Y, Aibara Y, Mohamad Yusoff F, Hidaka T, Kihara Y, Chayama K, Nakashima A, Goto C, Tomiyama H, Takase B, Kohro T, Suzuki T, Ishizu T, Ueda S, Yamazaki T, Furumoto T, Kario K, Inoue T, Koba S, Watanabe K, Takemoto Y, Hano T, Sata M, Ishibashi Y, Node K, Maemura K, Ohya Y, Furukawa T, Ito H, Ikeda H, Yamashina A and Higashi Y.

  Diagnostic Criteria of Flow-Mediated Vasodilation for Normal Endothelial Function and Nitroglycerin-Induced Vasodilation for Normal Vascular Smooth Muscle Function of the Brachial Artery.

  J Am Heart Assoc . 2020; 9:e013915.

• Daijo K, Nakahara T, Inagaki Y, Nanba M,Nishida Y, Uchikawa S, Kodama K, Oya K, Morio K, Fujino H, Ono A, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Hayes CN,Imamura M, Aikata H, Ochi H and Chayama K.

  Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases.

  J Gastroenterol Hepatol . 2020; In Press.

• Fujii Y, Doi M, Tsukiyama N, Hattori Y, Ohya K, Shiroma N, Morio K, Morioka T, Aikata H, Shinozaki K and Chayama K.

  Sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine(T-DM1) in advanced breast cancer.

  Int Cancer Conf J . 2020; 9: 18-23.

• Kawaguchi I, Chayama K, Gonzalez YS, Virabhak S, Mitchell D,Yuen C and Kumada H.

  A Cost-Effectiveness Analysis of Glecaprevir / Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.

  Adv Ther . 2020; 37 457-476.

• Johira Y, Hatooka H, Mori N, Fukuhara T, Takaki S, Shimomura Y,Imamura M, Hayes CN, Tsuji K and Chayama K.

  Regression of Idiopathic Thrombocytopenic Purpura in a Patient With Eradication of Hepatitis C Virus by Direct-Acting Antivirals.

  Hepatology . 2020; 71: 389-391.

• Yorita N, Oka S, Tanaka S, Kotachi T, Nagasaki N, Hata K,Kuroki K, Masuda K, Kurihara M, Kiso M, Boda T, Ito M and Chayama K.

  Clinical Usefulness of Dual Red Imaging in Gastric Endoscopic Submucosal Dissection: A Pilot Study.

  Clin Endosc . 2020; 53: 54-59.

• Kawaoka T, Ando Y, Yamauchi M, Suehiro Y, Yamaoka K, Kosaka Y,Fuji Y, Uchikawa S, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Takahashi S, Tsuge M, Hiramatsu A,Imamura M, Chayama K and Aikata H.

  Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab.

  Hepatol Res . 2020; In Press.

• Nakamura K, Urabe Y, Kagemoto K, Yuge R, Hayashi R, Ono A, Hayes CN, Oka S, Ito M, Nishisaka T, Tanabe K, Arihiro K, Ohdan H, Tanaka S and Chayama K.

  Genomic Characterization of Non-Invasive Differentiated-Type Gastric Cancer in the Japanese Population.

  Cancers(Basel) . 2020; 12: In Press.

• Makokha GN, Abe-Chayama H, Chowdhury S, Hayes CN, Tsuge M, Yoshima T, Ishida Y, Zhang Y, Uchida T, Tateno C, Akiyama R and Chayama K.

  Publisher Correction: Regulation of the Hepatitis B virus replication and gene expression by the multi-functional protein TARDBP.

  Sci Rep . 2020; 10: 2233.

• Ando Y, Yamauchi M, Suehiro Y, Yamaoka K, Kosaka Y, Fuji Y, Uchikawa S,Kodama K, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T,Takahashi S, Tsuge M, Hiramatsu A, Imamura M, Chayama K and Aikata H.

  Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability.

  Clin J Gastroenterol . 2020; In Press.

• Saito Y, Imamura M, Uchida T, Osawa M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Serikawa M, Aikata H, Abe-Chayama H, Hayes CN and Chayama K.

  Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.

  J Med Virol . 2020; 92: 210-218.

• Namba M, Hiramatsu A, Aikata H, Kodama K, Uchikawa S, Ohya K, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Tsuge M, Imamura M and Chayama K.

  Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.

  J Gastroenterol . 2020; 55: 217-226.

• Ito M, Tanaka S and Chayama K.

  Characteristics and Early Diagnosis of GastricCancer Discovered after Helicobacter pylori Eradication.

  Gut Liver . 2020; In Press.

• Maruhashi T, Kajikawa M, Kishimoto S, Hashimoto H, Takaeko Y, Yamaji T, Harada T, Hashimoto Y, Han Y, Aibara Y, Yusoff FM, Hidaka T,Chayama K, Nakashima A, Goto C, Kihara Y and Higashi Y.

  Vascular function is further impaired in subjects aged 80 years or older.

  Hypertens Res . 2020; In Press.

• Wakai M, Hayashi R, Tanaka S, Naito T, Kumada J, Nomura M, Takigawa H,Oka S, Ueno Y, Ito M and Chayama K.

  Serum amyloid A is a better predictive biomarker of mucosal healing than C-reactive protein in ulcerative colitis in clinical remission.

  BMC Gastroenterol . 2020; 20: 85.

• Ohya K, Kawaoka T, Imamura M, Morio K, Nakahara T, Murakami E,Yamauchi M, Hiramatsu A, Tsuge M, Aikata H and Chayama K.

  Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection.

  Intern Med . 2020; 59 941-944.

• Hata K, Ito M, Boda T, Kotachi T, Kiso M, Hiyama Y, Kuroki K, Yorita N, Nagasaki N, Abduwaili M, Tanaka S and Chayama K.

  The Evaluation of Esophageal Motility Using Infusion Manometry with a Trans-nasal Endoscope: A Preliminary Study.

  Intern Med . 2020; 59: 887-890.

• Ohya K, Imamura M, Osawa M, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Hiramatsu A, Tsuge M, Aikata H, Hayes CN and Chayama K.

  Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy.

  Clin J Gastroenterol . 2020; 13: 267-270.

• Uchikawa S, Kawaoka T, Namba M, Kodama K, Ohya K, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M,Takahashi S, Chayama K and Aikata H.

  Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients.

  Liver Cancer . 2020; 9: 148-155.

• Miyayama Y, Lee H, Song H,Abe-Chayama H, Miki D, Imamura M, Chayama K and Hijikata M.

  Comparative study on the replication of HCV1b genome between wild-type and cell culture-adaptive mutant in regard to sensitivities against anti-HCV drugs.

  Microbiol Immunol . 2020; 64:296-303.

• Okamoto K, Koda M, Okamoto T, Onoyama T, Miyoshi K, Kishina M, Matono T, Kato J, Tokunaga S, Sugihara T, Hiramatsu A, Hyogo H, Tobita H, Sato S, Kawanaka M, Hara Y, Hino K, Chayama K, Murawaki Y and Isomoto H.

  Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease.

  PLoS One . 2020; 15: e0219412.

• Otani I, Oka S, Tanaka S, Iio S, Tsuboi A, Kunihara S, Hiyama Y and Chayama K.

  Diagnostic Yield of Colon Capsule Endoscopy in Detection of Superficial Colorectal Lesions.

  Digestion . 2020; 101: 262-269.